518 related articles for article (PubMed ID: 31387579)
1. Identifying subpathway signatures for individualized anticancer drug response by integrating multi-omics data.
Xu Y; Dong Q; Li F; Xu Y; Hu C; Wang J; Shang D; Zheng X; Yang H; Zhang C; Shao M; Meng M; Xiong Z; Li X; Zhang Y
J Transl Med; 2019 Aug; 17(1):255. PubMed ID: 31387579
[TBL] [Abstract][Full Text] [Related]
2. Identification and comprehensive characterization of lncRNAs with copy number variations and their driving transcriptional perturbed subpathways reveal functional significance for cancer.
Xu Y; Wu T; Li F; Dong Q; Wang J; Shang D; Xu Y; Zhang C; Dou Y; Hu C; Yang H; Zheng X; Zhang Y; Wang L; Li X
Brief Bioinform; 2020 Dec; 21(6):2153-2166. PubMed ID: 31792500
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of mRNA-level and miRNA-level subpathway activities for identifying robust ovarian cancer prognostic signatures.
Tian S; Mi W; Zhang M; Xing L; Zhang C
J Cell Mol Med; 2020 Feb; 24(4):2582-2592. PubMed ID: 31957240
[TBL] [Abstract][Full Text] [Related]
4. Identification of Cancer Dysfunctional Subpathways by Integrating DNA Methylation, Copy Number Variation, and Gene-Expression Data.
Liu S; Zheng B; Sheng Y; Kong Q; Jiang Y; Yang Y; Han X; Cheng L; Zhang Y; Han J
Front Genet; 2019; 10():441. PubMed ID: 31156704
[TBL] [Abstract][Full Text] [Related]
5. Identifying individualized risk subpathways reveals pan-cancer molecular classification based on multi-omics data.
Xu Y; Wang J; Li F; Zhang C; Zheng X; Cao Y; Shang D; Hu C; Xu Y; Mi W; Li X; Cao Y; Zhang Y
Comput Struct Biotechnol J; 2022; 20():838-849. PubMed ID: 35222843
[TBL] [Abstract][Full Text] [Related]
6. Identification of Subpathway Signatures For Ovarian Cancer Prognosis by Integrated Analyses of High-Throughput miRNA and mRNA Expression.
Tian S; Tian J; Chen X; Li L; Liu Y; Wang Y; Sun Y; Zhang C; Lou G
Cell Physiol Biochem; 2017; 44(4):1325-1336. PubMed ID: 29183027
[TBL] [Abstract][Full Text] [Related]
7. A comprehensive overview of oncogenic pathways in human cancer.
Li F; Wu T; Xu Y; Dong Q; Xiao J; Xu Y; Li Q; Zhang C; Gao J; Liu L; Hu X; Huang J; Li X; Zhang Y
Brief Bioinform; 2020 May; 21(3):957-969. PubMed ID: 31155677
[TBL] [Abstract][Full Text] [Related]
8. Identification of novel prognostic biomarkers by integrating multi-omics data in gastric cancer.
Liu N; Wu Y; Cheng W; Wu Y; Wang L; Zhuang L
BMC Cancer; 2021 Apr; 21(1):460. PubMed ID: 33902514
[TBL] [Abstract][Full Text] [Related]
9. MOBCdb: a comprehensive database integrating multi-omics data on breast cancer for precision medicine.
Xie B; Yuan Z; Yang Y; Sun Z; Zhou S; Fang X
Breast Cancer Res Treat; 2018 Jun; 169(3):625-632. PubMed ID: 29429018
[TBL] [Abstract][Full Text] [Related]
10. Optimal drug prediction from personal genomics profiles.
Sheng J; Li F; Wong ST
IEEE J Biomed Health Inform; 2015 Jul; 19(4):1264-70. PubMed ID: 25781964
[TBL] [Abstract][Full Text] [Related]
11. Improved anticancer drug response prediction in cell lines using matrix factorization with similarity regularization.
Wang L; Li X; Zhang L; Gao Q
BMC Cancer; 2017 Aug; 17(1):513. PubMed ID: 28768489
[TBL] [Abstract][Full Text] [Related]
12. Identification of candidate cancer drivers by integrative Epi-DNA and Gene Expression (iEDGE) data analysis.
Li A; Chapuy B; Varelas X; Sebastiani P; Monti S
Sci Rep; 2019 Nov; 9(1):16904. PubMed ID: 31729402
[TBL] [Abstract][Full Text] [Related]
13. Integrating gene and lncRNA expression to infer subpathway activity for tumor analyses.
Zhang C; Xu Y; Yang H; Xu Y; Dong Q; Liu S; Wu T; Zhang Y
Oncotarget; 2017 Dec; 8(67):111433-111443. PubMed ID: 29340065
[TBL] [Abstract][Full Text] [Related]
14. The Need for Multi-Omics Biomarker Signatures in Precision Medicine.
Olivier M; Asmis R; Hawkins GA; Howard TD; Cox LA
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31561483
[TBL] [Abstract][Full Text] [Related]
15. Computational identification of multi-omic correlates of anticancer therapeutic response.
Stetson LC; Pearl T; Chen Y; Barnholtz-Sloan JS
BMC Genomics; 2014; 15 Suppl 7(Suppl 7):S2. PubMed ID: 25573145
[TBL] [Abstract][Full Text] [Related]
16. DROEG: a method for cancer drug response prediction based on omics and essential genes integration.
Wu P; Sun R; Fahira A; Chen Y; Jiangzhou H; Wang K; Yang Q; Dai Y; Pan D; Shi Y; Wang Z
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36715269
[TBL] [Abstract][Full Text] [Related]
17. EMT network-based feature selection improves prognosis prediction in lung adenocarcinoma.
Shao B; Bjaanæs MM; Helland Å; Schütte C; Conrad T
PLoS One; 2019; 14(1):e0204186. PubMed ID: 30703089
[TBL] [Abstract][Full Text] [Related]
18. Bayesian variable selection with graphical structure learning: Applications in integrative genomics.
Kundu S; Cheng Y; Shin M; Manyam G; Mallick BK; Baladandayuthapani V
PLoS One; 2018; 13(7):e0195070. PubMed ID: 30059495
[TBL] [Abstract][Full Text] [Related]
19. Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach.
Ali M; Khan SA; Wennerberg K; Aittokallio T
Bioinformatics; 2018 Apr; 34(8):1353-1362. PubMed ID: 29186355
[TBL] [Abstract][Full Text] [Related]
20. Gene-centric multi-omics integration with convolutional encoders for cancer drug response prediction.
Lee M; Kim PJ; Joe H; Kim HG
Comput Biol Med; 2022 Dec; 151(Pt A):106192. PubMed ID: 36327883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
